About Biogen
Funding & Growth
✓ Pros
- • Leader in neuroscience
- • Cambridge, MA location
- • Strong MS portfolio
- • Pioneer in biotech
- • Good benefits
✗ Cons
- • Alzheimer's drug challenges
- • Recent restructuring
- • Stock volatility
- • Competitive landscape
🏢 Working Here
Biogen is headquartered in Cambridge, MA (Kendall Square), making it unique among large biopharma in having its entire computational biology operation in the heart of Boston's biotech ecosystem.
Founded in 1978 by Nobel laureates, Biogen maintains singular focus on neuroscience: MS (Tysabri, Tecfidera), SMA (Spinraza), and Alzheimer's (Leqembi with Eisai).
This specialization combined with the Cambridge location creates exceptional opportunities for computational neuroscientists.
Direct access to neurologists at Mass General, Brigham, Harvard Medical School, and collaborations with Broad Institute's neuroscience programs is a major advantage.
Bioinformaticians work on MS immunology, neurodegenerative disease genetics and biomarkers, rare neurogenetic disorders, and digital biomarkers from wearables and smartphones.
The company has world-class computational infrastructure with strong AI/ML emphasis for CNS drug discovery.
Work involves analyzing brain imaging (MRI volumetrics, amyloid/tau PET), CSF biomarkers (neurofilament, amyloid, tau), genetics of rare neurological diseases, and smartphone-based digital biomarkers.
Being entirely Cambridge-based means easy cross-team collaboration, walking distance to academic partners, and full immersion in Boston's neuroscience community.
🧬 Bioinformatics Focus
Biogen's computational biology is uniquely focused on neuroscience. Core areas:
- Neurodegeneration biomarkers - analyzing amyloid PET, tau PET, MRI volumetrics, CSF biomarkers from Alzheimer's and Parkinson's trials, understanding disease progression, predicting cognitive decline,
- Multiple sclerosis - analyzing MRI lesions, immune cell profiling in MS patients, understanding disease subtypes, predicting treatment response to Tysabri, Tecfidera, newer agents,
- Rare neurogenetic diseases - analyzing SMA patient genetics and outcomes from Spinraza, understanding mechanisms for ALS, Friedreich's ataxia, and other rare disorders,
- Digital biomarkers - analyzing smartphone passive data (typing, walking), wearable sensors, remote cognitive testing as outcome measures and progression markers,
- Alzheimer's genetics - analyzing APOE and other genetic risk factors, integrating genetics with imaging and fluid biomarkers. Biogen maintains longitudinal cohorts with deep phenotyping including serial brain imaging spanning years. Technical challenges include analyzing brain imaging at scale, integrating multi-modal neurological data, dealing with slow disease progression (years to decades), and developing digital biomarkers validated for regulatory use. The Leqembi development involved pioneering regulatory strategies for amyloid-targeting therapies.
📈 Career Growth & Development
Career Paths
Scientist Track
Leadership Track
Compensation
Compensation is competitive with 15-20% bonuses, stock grants, and strong benefits. The Cambridge location offers premium pay.
Development
Biogen supports professional development through courses, conferences, and collaborations with academic neurologists. Publications are encouraged, particularly for novel biomarker work.
Mobility
Many Biogen scientists become recognized experts and are recruited by other companies or take faculty positions. The alumni network is strong in the neuroscience sector.
Expertise
Biogen values neuroscience expertise, with many scientists specializing in MS, Alzheimer's, or rare diseases. This specialized focus is both a strength and a risk.
💊 Top Medicines & Blockbuster Drugs
Tysabri (natalizumab)
2004Indication: Relapsing forms of multiple sclerosis
Integrin inhibitor - continued strong sales
Annual Revenue (USD)
Spinraza (nusinersen)
2016Indication: Spinal muscular atrophy (SMA)
First SMA treatment - antisense oligonucleotide
Annual Revenue (USD)
Tecfidera (dimethyl fumarate)
2013Indication: Relapsing forms of multiple sclerosis
Was Biogen's top drug - facing generics
Annual Revenue (USD)
Vumerity (diroximel fumarate)
2019Indication: Relapsing forms of multiple sclerosis
Improved GI tolerability vs Tecfidera
Annual Revenue (USD)
Leqembi (lecanemab)
2023Indication: Early Alzheimer's disease
Anti-amyloid antibody - Eisai partnership, ramping
Annual Revenue (USD)